Antitumor immuno-virotherapy with attenuated strains of measles virus (notice n° 1529045)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01752cam a2200181 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251012013307.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Fonteneau, Jean-François |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Antitumor immuno-virotherapy with attenuated strains of measles virus |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 5 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Antitumor immuno-virotherapy involves the use of replicating oncolytic viruses capable of selectively infecting and killing tumor cells, with the aim of stimulating an antitumor immune response. Attenuated strains of measles virus (MeV) used as measles vaccines are good candidates. Attenuated MeVs use the CD46 molecule as a tumor cell entry receptor, but also CD150/SLAM and Nectin-4. The CD46 molecule blocks complement-mediated lysis and is frequently overexpressed by many cancer cell types, enabling the attenuated MeV to infect these cells. In addition, MeVs take advantage of defects in the antiviral type I interferon (IFN I) response in tumor cells to replicate, while this antiviral response blocks its replication in healthy cells. Attenuated MeVs display oncolytic properties against numerous cancers in vitro and in mouse models. They induce immunogenic cell death with infiltration of tumors by immune cells, notably T lymphocytes, thus activating the anti-tumor immune response. Several phase I and II clinical trials using different MeVs have been carried out, with encouraging results. Here, we provide an update on this therapeutic approach. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Boisgerault, Nicolas |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tangy, Frédéric |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Virologie | 29 | 4 | 2025-09-03 | p. 271-291 | 1267-8694 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-virologie-2025-4-page-271?lang=en&redirect-ssocas=7080">https://shs.cairn.info/journal-virologie-2025-4-page-271?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux